drugset

drugset / Trial / NCT06329687

A Study Evaluating the Safety of the Nasal Pump

NCT06329687 ↗

Phase 4 Terminated 5 enrolled Oyster Point Pharma, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine the safety of the Tyrvaya nasal pump.

Timeline

Start: 2024-02-21
Primary completion: 2024-02-28
Completion: 2024-02-28

Outcome

Outcome not reported

Stopped (Business): “Internal strategy change. Not related to safety concerns.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tyrvaya Nasal Pump	Unknown	—	Intranasal

Indications